White Paper

Building on APACMed’s advocacy work on the “Value of Diagnostics”, this paper aims to continue highlighting the substantial value in-vitro diagnostics provide to patients, healthcare professionals, providers/laboratory professionals, policy-makers and payers in the Asia Pacific region. Through extensive research and multi-stakeholder interviews, done in partnership with ANSEA, this paper proposes 5 practical recommendations for policy-makers to enable better patient access & funding, with a practical comprehensive fit-for-purpose value assessment framework for in-vitro diagnostics (IVDs), in the case of cardiovascular diseases (coronary artery disease and heart failure).

Roundtable: A Deep Dive into Australia’s and Thailand’s Access Policies

On 21 November 2023, APACMed and ANSEA Consulting organised a closed-door roundtable session on the Value of Diagnostics in Cardiovascular Diseases with a focus on Australia and Thailand. Key stakeholders, encompassing policymakers, payors, academics, clinicians, and local trade associations, from Australia and Thailand were present during the session. This report summarises the discussions centred around the sharing of best practices as well as the exploration of opportunities and challenges associated with the implementation of policy recommendations outlined in the White Paper. Policymakers, healthcare providers, and industry leaders who are working to advance cardiovascular diagnostics within the Asia Pacific region will find this report insightful.